Meitheal Pharmaceuticals Expands Medical Affairs Operations with Two Appointments

Meitheal Pharmaceuticals, Inc. (Meitheal), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, appointed Dr. Keith Robinson as Chief Medical Officer. 

Additionally, Dr. Lonnie Brent has been appointed Senior Vice President of Medical Affairs and will lead Meitheal’s recently formed Medical Affairs operation.  

The recently formed and now expanding Medical Affairs team will play a pivotal role in the research and development of the company’s portfolio of 70 on-market products and growth into the anti-infective space. Infectious disease is a key therapeutic area where the company is strategically investing to ensure Meitheal’s long-term growth. 

In 2024, Meitheal gained exclusive commercial licensing rights for two antibiotics, fosfomycin for injection and XENLETA (lefamulin). These two medicines are designed to address the unmet issue of increasing antibiotic resistance and, following regulatory approval and commercialization, could have a positive impact on individuals in both inpatient and outpatient treatment settings.  

Robinson is an experienced critical care and pulmonary physician with 18 years of clinical experience. Before joining Meitheal, Robinson most recently served as Executive Medical Director at Syneos Health, where he led initiatives in pulmonary, critical care, and general medicine. Before Syneos, Robinson served as the Associate Medical Director at IQVIA, managing pulmonary and critical care medicine projects. 

Brent is a Doctor of Pharmacy by trade and has over 20 years of experience in pharmaceuticals, research and development, Medical Affairs, and deep expertise in oncology, rare diseases, and clinical practice to build and lead Meitheal’s Medical Affairs function. Before joining Meitheal, Brent served as Senior Vice President of Medical Affairs at TerSera Therapeutics, where he led the Medical Affairs function and served on the organization’s extended leadership team. While at TerSera, he served as interim Chief Medical Officer during key leadership transitions.

“With a combined 38 years of experience in clinical research and development and Medical Affairs, Keith and Lonnie join Meitheal at a critical point in our evolution to become a more diversified and innovation-driven biopharmaceutical organization,” said Tom Shea, CEO of Meitheal. “These strategic appointments reflect not only our confidence in Meitheal’s long-term growth but also the important steps we are taking to expand our capabilities as our pipeline advances – particularly with two medicines in the antibiotics space.”